Company profile: Caliber Therapeutics
1.1 - Company Overview
Company description
- Provider of stent-free targeted angioplasty drug delivery solutions, featuring the Virtue Sirolimus AngioInfusion Balloon, an investigational drug/device delivering extended-release sirolimus during balloon angioplasty without coating or permanent implant, and BackBeat Cardiac Neuromodulation Therapy, an investigational bioelectronic treatment for hypertension that modulates autonomic nervous system responses.
Products and services
- Targeted Angioplasty Drug Delivery balloon: A stent-free platform enabling targeted intravascular delivery of anti-restenotic drugs during angioplasty, supporting localized drug administration to address restenosis risk without permanent implants
- Virtue® Sirolimus AngioInfusion™ Balloon (SAB): An investigational drug/device combination balloon that delivers an extended-release formulation of sirolimus during angioplasty, achieving controlled anti-restenotic drug transfer without balloon coating or a permanent implant
- BackBeat Cardiac Neuromodulation Therapy™ (BackBeat CNT™): A bioelectronic therapy for hypertension that aims to reduce blood pressure by modulating autonomic nervous system responses
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Caliber Therapeutics
VNUS
HQ: United States
Website
- Description: Provider of products and minimally invasive treatments for venous diseases, including the patented Closure System for patients with symptoms associated with venous reflux; a world leader in the development and marketing of minimally invasive treatments for venous diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VNUS company profile →
Aegerion Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics to treat cardiovascular and metabolic diseases, focused on the development and commercialization of therapies, including lomitapide (AEGR-733), a microsomal triglyceride transfer protein inhibitor small molecule drug designed to decrease serum lipids.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aegerion Pharmaceuticals company profile →
AUM Cardiovascular
HQ: United States
Website
- Description: Provider of medical device manufacturing solutions specializing in the biotechnology, medical, and healthcare fields.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AUM Cardiovascular company profile →
Carmeda
HQ: Sweden
Website
- Description: Provider of hemocompatible surface coating for medical devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carmeda company profile →
Deltex Medical
HQ: United Kingdom
Website
- Description: Provider of haemodynamic monitoring solutions using oesophageal Doppler technology, including the TrueVue system with improved signal acquisition, intuitive software and HD touchscreen controls; ODM+ devices to guide fluid and drug administration; the NICE-recommended CardioQ-ODM; plus e-learning courses and an Oesophageal Doppler Simulator.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Deltex Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Caliber Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Caliber Therapeutics
2.2 - Growth funds investing in similar companies to Caliber Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Caliber Therapeutics
4.2 - Public trading comparable groups for Caliber Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →